Grant ID RP140515
Awarded On August 20, 2014
Title CDK Inhibitors as Adjunctive to 5-FU and/or Radiation in Esophageal Adenocarcinoma- Assessment of Efficacy and Predictive Biomarkers
Program Academic Research
Award Mechanism Individual Investigator
Institution/Organization The University of Texas M.D. Anderson Cancer Center
Principal Investigator/Program Director Dipen Maru
Cancer Sites Head and Neck
Contracted Amount $882,133
Lay Summary

Patients with esophageal adenocarcinoma localized to esophagus and surrounding lymph nodes are treated with chemotherapy and radiation followed by surgical resection of esophagus. In spite of this aggressive therapy, 5 year survival is poor (20-25%). There is a dire need to increase sensitization of tumor to chemoradiotherapy to improve survival of these patients. Cyclin dependent kinase 9 is a critical enzyme for maintenance of several proteins which affect cell death (apoptosis). We propose to study the utility of cyclin dependent kinase (CDK) inhibitors with CDK 9 inhibitory activities in increasing sensitivity of esophageal carcinoma to commonly used chemotherapeutic agent 5-Fluouracil (...

Read More